Biomet Still Under Scrutiny For Overseas Bribery
This article was originally published in The Gray Sheet
The company came under a Department of Justice inquiry for overseas bribery in 2012, and new allegations in 2014 have delayed a final close-out of the case. The formal agreements expired on March 26, but Biomet says it expects the investigation to continue.
You may also be interested in...
Recently inaugurated Mexican President Andrés Manuel López Obrador campaigned on a promise to tackle the country’s corruption issues. Medtech Insight spoke to attorney Nicholas Berg, of Ropes & Gray, about what this may mean for device manufacturers doing business in Mexico.
The orthopedic device company is set to pay $17.4m to the US Department of Justice and an additional $13m to the Securities and Exchange Commission to resolve allegations that Biomet didn’t stop corrupt acts in Brazil and Mexico even after a 2012 deferred prosecution agreement.
Analogic Corp. and its subsidiary BK Medical APS are paying almost $15m to settle allegations that BK conspired with distributors to commit fraud overseas.